IN-VITRO GLUCOCORTICOID STUDIES FOR PREDICTING RESPONSE TO GLUCOCORTICOID THERAPY IN ADULTS WITH MALIGNANT LYMPHOMA

Clara D. Bloomfield, Bruce A. Peterson, Joann Zaleskas, Glauco Frizzera, Kendall A. Smith, Laurie Hildebrandt, Kazimiera J. Gajl-Peczalska, Allan Munck

Research output: Contribution to journalArticle

40 Scopus citations

Abstract

Neoplastic tissues from 28 adults with malignant lymphoma were examined for glucocorticoid receptors and in-vitro sensitivity to glucocorticoids. The patients were then treated with dexamethasone for 5-14 days. 13 patients achieved at least a partial remission, and 15 had no significant tumour response. Lymphoma cells from patients who responded had more glucocorticoid-receptor sites per cell and greater in-vitro sensitivity as measured by glucocorticoid inhibition of incorporation of leucine and uridine than did tumour cells from non-responders. Study of tumour glucocorticoid receptors and glucocorticoid sensitivity in vitro may allow selection of those patients with lymphoma who should receive glucocorticoids as part of combination chemotherapy.

Original languageEnglish (US)
Pages (from-to)952-956
Number of pages5
JournalThe Lancet
Volume315
Issue number8175
DOIs
StatePublished - May 3 1980

Fingerprint Dive into the research topics of 'IN-VITRO GLUCOCORTICOID STUDIES FOR PREDICTING RESPONSE TO GLUCOCORTICOID THERAPY IN ADULTS WITH MALIGNANT LYMPHOMA'. Together they form a unique fingerprint.

  • Cite this

    Bloomfield, C. D., Peterson, B. A., Zaleskas, J., Frizzera, G., Smith, K. A., Hildebrandt, L., Gajl-Peczalska, K. J., & Munck, A. (1980). IN-VITRO GLUCOCORTICOID STUDIES FOR PREDICTING RESPONSE TO GLUCOCORTICOID THERAPY IN ADULTS WITH MALIGNANT LYMPHOMA. The Lancet, 315(8175), 952-956. https://doi.org/10.1016/S0140-6736(80)91405-1